Efficacy of Growth Factor in Promoting Early Osseointegration

Abstract

A preclinical study was conducted to evaluate the feasibility of 2 different topical formulations of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) to promote early osseointegration and enhanced bone-to-implant contact (BIC) for dental implants placed in an edentulous ridge. Six female beagle dogs were divided into 3 groups. The control group included 4 implants with no coating; test group A included 10 implants with commercially available rhPDGF-BB formulation coating; and second test group B included 10 implants with prototype viscous rhPDGF-BB coating. Three dogs were sacrificed at 3 weeks (12 implants) and the remaining 3 dogs at 6 weeks after implant placement (12 implants). The specimens were retrieved for histological evaluation, and revealed an uneventful healing of all implants without any sign of an inflammatory response at the different time intervals. Furthermore, the bone was in very close contact with the implants' surfaces with no evidence of intervening fibrous tissue layers. At 3 weeks, new bone formation between most implant threads on rhPDGF-BB coated implants was evident, whereas in the control group only a thin and sparse amount of new bone was noted. At 6 weeks, the commercially available rhPDGF-BB formulation coated implant group (Group A) showed more trabecular bone and higher BIC compared to the other 2 groups. Histologically, the results in this study showed that use of conventionally available rhPDGF-BB formulation as the implant surface treatment may accelerate the process of osseointegration and enhance BIC.

Platelet Adhesion on Commercially Pure Titanium Plates in Vitro II. Immunofluorescence Visualization of PDGF-B, TGFβ1, and PPARγ Released from Activated Adherent Platelets

“…PDGF, TGFβ, and PPARγ have been often demonstrated to have potential positive effects. PDGF enhances bone formation and bone-to-implant contact through direct activation of osteoblasts, in addition to recruitment of mesenchymal stem cells through vascularization [33], and consequently accelerates the process of osseointegration [34][35][36]. Although being unable to directly induce osteogenesis in stem cells, TGFβ1 increases the pool of osteoprogenitors by inducing chemotaxis and proliferation [37].…”

Platelet-rich plasma improves initial bone remodeling

“…Correction of bone defects in the installation of dental implants can be accelerated by adding platelet-rich plasma (PRP) material that can initiate wound healing by releasing locally employed growth factors. [1][2][3] Platelet-rich plasma is a protein taken autologous, using regeneration of the body itself, so it has the advantage that; PRP can prevent disease transfer and immunologic reactions, PRP is easy to obtain because it comes from self-administered animal blood, time is short, easy and safe to apply, PRP has high fibrin content, PRP accelerates epithelial, endothelial and epidermal regeneration which can promote tissue healing through angiogenesis and collagen synthesis, PRP can accelerate bone formation and maturation. 4 Bone formation begins with the release of platelet derive growth factor (PDGF), TGF and IGF.…”

Sustained Protein Release from a Core‐Shell Drug Carrier System Comprised of Mesoporous Nanoparticles and an Injectable Hydrogel

“…A recent review similarly speculated that the supramolecular chemistry of organic materials such as hydrogels could leverage the therapeutically beneficial outcomes of mesoporous silica nanoparticles . This technology associated with the sustained release of recombinant proteins and small molecule drugs holds great promise for soft and hard tissue engineering . In order to promote healing and regeneration, many modern constructs are optimized to deliver bioactive molecules to affect either co‐delivered cells or the local cellular milleau .…”